Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We ...
Publications
View AllManagement of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperg...
Institution Info
- Type
- education
- Country
- GB
- Publications
- 2
- Citations
- 9,005
External Links
Identifiers
- ROR
- https://ror.org/03mf1cy35